Eckert & Ziegler: New Board member Dr. André Heß to direct radiopharmaceuticals segment

Berlin, 22 February 2008. The Supervisory Board of Eckert & Ziegler AG (ISIN DE 0005659700) has appointed Dr. André Heß to be the third member of the Executive Board as of 1 March 2008. He will assume directorship of the radiopharmaceuticals segment with the objective of evolving this segment into a strong pillar of the group.

Following his studies in chemistry and economic engineering as well as a research position (wissenschaftlicher Mitarbeiter) at the Humboldt University in Berlin, André Heß joined what would become Eckert & Ziegler AG as a radiochemist in 1996, where he directed the development department. In 1999 he was appointed managing director of Eckert & Ziegler Eurotope GmbH, which develops and markets radioactive medical implants as well as the associated production technology on an international scale. Since 2005 he has been in charge of development, production, and sales of innovative radiopharmaceutical synthesis systems as well as customized development for radiopharmaceutical production technologies within the radiopharmaceuticals segment of Eckert & Ziegler AG.

In the words of Supervisory Board Chairman Professor Wolfgang Maennig, "With the Modular Lab family of synthesis systems, André Heß and his team have demonstrated over the past years that they can successfully develop and introduce new products onto the market. It is therefore only logical to give Mr. Heß greater responsibilities and to make use of his abilities for the entire segment. We see considerable opportunities for growth in the radiopharmaceuticals sector for Eckert & Ziegler. With the appointment of Mr. Heß, we want to ensure that sufficient management capacities are available for further expansion."

With more than 370 employees worldwide, Eckert & Ziegler AG is one of the leading suppliers of radioactive applications in medicine, research, and industry. The company anticipates sales of approximately 60 million euros in 2008, of which products from the radiopharmaceuticals segment will account for around 12 million euros. These include automated synthesis systems for radiodiagnostics as well as contrast agents for positron emission tomography (PET).

The Board of Directors